Skip to main content
KRRO logo

KRRO

Korro Bio, Inc.
$14.72 +0.23 (+1.59%) At close · Jul 8
Market Cap
$212.30M
Shares
14,422,571

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.72 Open$14.29 Day$14.10–15.20 52W$5.20–55.89 Avg vol 30d243K Short int1.3M · 9.1% float · 9.1d Short vol79% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 7
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg +21%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 19%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +39%
trailing
6-month return +64%
trailing
YTD return +84%
this year
Relative strength +56%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $12 › 200d $17 — 200d above 50d
Institutional flow Distributing
2 of 99 funds reported for Jun 30 · net -28 sh shares
Insider flow Distributing
Net -$416.1K over 90 days · 100% sells
Short interest Rising
9.15% of float · ▲ +4.3% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
99 holders — near 2-yr high, broad support
Squeeze score 86
high risk · 0–100
Fundamentals
Fair
Revenue growth +181%
Y/Y
EPS growth −33%
Y/Y
Free cash flow $-79.1M
Balance sheet $21.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 125%
annualized · 1-yr
Max drawdown −90%
past year
ATR 8.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Aug 10, 2026 Est · unconfirmed · in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 7, 2026

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
+21% Bullish
RSI (14)
65 Neutral
MACD trend
Positive Bullish
52-week position
19% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $12 › 200d $17 — 200d above 50d
Institutional flow Distributing
2 of 99 funds reported for Jun 30 · net -28 sh shares
Insider flow Distributing
Net -$416.1K over 90 days · 100% sells
Short interest Rising
9.15% of float · ▲ +4.3% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
99 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $5 Now $15 · 19% 52-wk high $56
vs 200-day avg -11% vs 50-day avg +21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KRRO
Korro Bio, Inc.
this stock
$212.30M +83.8% +181.5% 9.1%
ONC
BeOne Medicines Ltd.
$446.53B +1.7% +22179.2% 908.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$126.50B +9.9% +46.2% 29.6 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$69.50B -14.0% +20.8% 16.2 3.2%
ARGX
Argenx SE
$57.20B +8.8% 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
99
% held
91.1%
Reported
2 of 99
Top holder
Lynx1 Capital Management…
Held Float
View
Held by Funds
Fund positions
83
View
Short & Settlement
Short Interest Rising
Shares short
1.3M
Days to cover
9.1d
Change
+54.2K sh
View
Short Volume
Short vol %
79%
As of
Jul 8, 2026
Short Total
View
Fails to Deliver
FTD shares
51
Value
$537
As of
Jun 12, 2026
View
Off-Exchange
Off-exchange %
37.9%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$416.1K
Buyers / Sellers
0 / 6
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$6.4M
Net income (FY)
$-117.3M
EPS diluted
$-12.48
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 11, 2026
This year
10
View
Proposed Sales
Value
$34.3K
Shares
3.2K
Filed
Jun 16, 2026
View
Exempt Offerings
Offering
$42.3M
Filed
Jul 27, 2020
View
Earnings & Events
Earnings Calls
Last call
May 14, 2026
View

Performance

5D 20D 120D MTD YTD
KRRO +11.7% +39.0% +63.7% +11.7% +83.8%
SPY -0.2% +0.8% +7.4% -0.2% +9.3%
vs SPY +11.9% +38.2% +56.3% +11.9% +74.5%
Key facts CIK 1703647 CUSIP 500946108 13F (30d) 3 filings 3 filers Visit website Investor relations